Neos Therapeutics resubmits ADHD drug marketing application

(Reuters) - Drug developer Neos Therapeutics Inc said on Tuesday it resubmitted the marketing application for its attention deficit/hyperactivity disorder (ADHD) drug to the U.S. Food and Drug Administration.